Advertisement
News
Subscribe to MDT Magazine News

VIDEO from thenewsmarket.com and Novartis: Novartis drug Afinitor® Approved by FDA as First Medication for Children and Adults With a Benign Brain Tumor Associated With Tuber...

October 30, 2010 6:35 pm | by Bio-Medicine.Org | Comments

NEW YORK, Oct. 30 /- See video from Novartis at: http://www.thenewsmarket.com/Releases/StoryDetailPage.aspx?GUID=193bd015-3567-4799-8ee7-81dfac6c6369 Novartis announced that the US Food and Drug Administration (FDA) has approved Afinitor®; (everolimus) tablets for patients with...

TOPICS:

CDRH Aiming to Toughen Stance On Use of Old Predicate Devices

October 30, 2010 1:31 pm | by U.S. Food & Drug Administration | Comments

Amid calls from devicemakers to improve its policies on predicate devices and promises from CDRH to do so, the center is beginning to clarify changes that may be in the works as part of its 510(k) overhaul.

TOPICS:

Sen. Grassley Hunting for Link Between Medtronic, VA Adviser

October 30, 2010 1:31 pm | by U.S. Food & Drug Administration | Comments

In another inquiry into devicemaker ties, Sen. Chuck Grassley (R-Iowa) is questioning the exact nature of the relationship between Medtronic and a former consultant, Stephen Ondra, who now serves as a senior policy adviser at the Department of Veterans Affairs (VA).

TOPICS:
Advertisement

Donor race may impact recurrent hepatitis C in liver transplant patients

October 30, 2010 6:35 am | by EurekAlert | Comments

(Henry Ford Health System) The race of liver donors may affect recurrent hepatitis C in patients after liver transplant, according to a study by Henry Ford Hospital. "Patients receiving white cadaveric donor grafts had significantly more aggressive recurrent hepatitis C than those...

TOPICS:

ANA598 Data Presented at AASLD Highlight Positive Clinical Profile of DAA Entering Phase IIb

October 30, 2010 6:34 am | by Bio-Medicine.Org | Comments

SAN DIEGO, Oct. 30 /- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today announced the ANA598 data to be presented at the 61st Annual Meeting of the American Association for the Study of Liver Disease (AASLD) in Boston, MA.  ANA598, the Company's direct-acting antiviral (DAA) being...

TOPICS:

Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Int...

October 30, 2010 6:33 am | by Bio-Medicine.Org | Comments

BOSTON and RIDGEFIELD, Conn., Oct. 30, 2010 /- Boehringer Ingelheim Pharmaceuticals, Inc. announced today results from a Phase Ib study, SOUND-C1, that showed the combination of two oral hepatitis C virus (HCV) compounds, the protease inhibitor BI 201335 and the polymerase inhibitor BI...

TOPICS:

Achieving Sustained Viral Response for Patients with Recurrent Hepatitis C After Transplantation is Key for Long-Term Outcomes

October 30, 2010 6:33 am | by Bio-Medicine.Org | Comments

BOSTON, Oct. 30 /- Researchers from the University of Bari, Italy, concluded that treating patients after transplantation with antiviral therapy creates a sustained viral response (SVR) and protects them from liver-related deaths. The purpose of this study was to determine the long-term...

TOPICS:

Surrogate decision makers wish to retain authority in difficult decision

October 29, 2010 4:35 pm | by EurekAlert | Comments

(American Thoracic Society) The decision to stop life-support for incapacitated and critically ill patients is, for surrogate decision makers, often fraught with moral and ethical uncertainty, and long-term emotional consequences. But as difficult as these decisions are, more than half of...

TOPICS:
Advertisement

Allergy Update: Know your treatment options

October 29, 2010 4:34 pm | by Baylor College of Medicine | Comments

Allergies got you down? Dr. Madhu Narra , assistant professor of medicine in the section of allergy, immunology and rheumatology at Baylor College of Medicine discusses potential treatment options. Classic allergy symptoms include runny and itchy eyes and nose, sneezing, congestion,...

TOPICS:

Stryker acquires Porex Surgical

October 29, 2010 2:45 pm | by The Associated Press | Comments

Medical technology company Stryker Corp. is acquiring privately held Porex Surgical, a medical products company and division of Porex Corp.The terms of the deal were not disclosed.Stryker, which announced the deal Friday, said Porex's products — used primarily in reconstructive surgery of the...

PerkinElmer teams with LinaTech in radiotherapy

October 29, 2010 1:45 pm | by The Associated Press | Comments

Medical instrument maker PerkinElmer Inc. said Friday that it agreed to jointly develop and sell a radiotherapy technology with device maker LinaTech.Among the products is a cost-effective imaging solution that allows customers to upgrade their film-based radiotherapy systems, it said.The first...

Zebrafish yield clues to how we process visual information

October 29, 2010 1:35 pm | by Lawrence Berkeley National Laboratory | Comments

To a hungry fish on the prowl, the split-second neural processing required to see and gobble up prey is a matter of survival. To scientists, it’s a window into how our brain coordinates eye motions that enable us make our way in a world full of danger and opportunity. This process is now...

TOPICS:

Heparin Sodium (B. Braun): Recall - Trace Contaminant

October 29, 2010 1:31 pm | by U.S. Food & Drug Administration | Comments

Oversulfated chondroitin sulfate (OSCS) contaminant found during sample testing.

TOPICS:

Roche Introduces Immunoassay Module for cobas® 8000 Modular Analyzer Series In U.S.

October 29, 2010 10:31 am | by Bio-Medicine.Org | Comments

INDIANAPOLIS, Oct. 29 /- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the U.S. introduction of the cobas e 602 analyzer, the latest addition to the cobas® 8000 modular analyzer series for diagnostic labs with high-volume workloads. Labs will now be able to combine this new...

TOPICS:

Methotrexate Injection, 50mg/2mL and 250mg/10mL Vials: Recall - Presence of Glass Particulates

October 29, 2010 9:35 am | by U.S. Food & Drug Administration | Comments

Potential to develop adverse reactions in areas where the particles lodge, which could result in serious adverse events, disability, or death.

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading